NewLimit
NewLimit is a biotechnology startup combining AI, genomics, and epigenetic reprogramming to develop medicines targeting age-related diseases and extending healthy human lifespan
- Artificial Intelligence
- San Francisco, California, United States
Company Overview
NewLimit is a biotechnology company developing medicines designed to restore youthful function in aging cells and treat age-related diseases. Founded by Brian Armstrong, Blake Byers, and Jacob Kimmel, the company combines epigenetic reprogramming, functional genomics, large-scale biological experiments, and machine learning to discover potential therapeutic candidates.
QueryFeedz Insight
NewLimit sits at the intersection of biotechnology, AI-driven drug discovery, and longevity research. Rather than developing a general-purpose anti-aging product, the company is pursuing therapeutic programs designed to restore specific functions in aging cells. Its platform combines machine-learning predictions with large-scale experimental validation to search for epigenetic interventions that may improve cellular function.
Funding & Investors
- Latest funding
- $435
- Latest round
- Series C
- Latest funding date
- June 2026
Investors
- Founders Fund (lead investor),
- Thrive Capital,
- Greenoaks,
- Quiet Capital,
- Kleiner Perkins,
- Abstract, Nat Friedman and Daniel Gross,
- Valor Equity Partners,
- Eli Lilly Ventures,
- Human Capital,
- and other participating investors.
Founders
- Brian Armstrong — Co-Founder and Board Director; also Co-Founder and CEO of Coinbase. Blake Byers — Co-Founder; scientist and investor. Jacob C. Kimmel — Co-Founder and CEO; computational biologist with a background in stem-cell biology and epigenetic reprogramming.
